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KESAN ANDROGRAPHOLIDE KE ATAS PENGANGKUT ANION ORGANIK 
MANUSIA 1 (hOAT1) DAN RAMALAN RISIKO INTERAKSI UBAT-HERBA 
 
ABSTRAK 
Kepentingan dalam penggunaan ubat-ubatan berasaskan herba dan produk 
herba telah berkembang dengan pesat di seluruh dunia. Kefahaman mengenai potensi 
ke atas interaksi herba dan perubatan moden telah meningkat disebabkan populariti 
kandungan herba. Pengangkut ubat telah diiktiraf memainkan peranan utama dalam 
penyerapan, pengedaran, metabolisme dan penyingkiran ubat. Oleh sebab itu, 
interaksi antara ubat-ubatan dan pengangkut boleh berlaku. Pengangkut anion organik 
manusia 1 (hOAT1) memainkan peranan penting dalam pengedaran dan penghapusan 
pelbagai bahan dalaman dan xenobiotik. Hempedu bumi telah digunakan secara 
meluas untuk merawat selesema, cirit-birit, radang dan jangkitan saluran pernafasan. 
Dalam kajian ini, andrographolide merupakan sebatian bioaktif utama daripada 
hempedu bumi dan kesannya ke atas aktiviti pengambilan hOAT1 telah dinilaikan. 
Sel rekombinan CHO-K1 dengan ekspresi hOAT1 secara stabil (sel CHO-hOAT1) 
telah dihasilkan untuk mengkaji aktiviti pengangkutan hOAT1. Ekspresi hOAT1 
dalam sel CHO-hOAT1 telah disahkan dengan menggunakan analisis RT-qPCR dan 
Western blot. Aktiviti pengambilan hOAT1 telah dijalankan untuk menentukan sama 
ada andrographolide adalah substrat atau perencat kepada hOAT1. Hasil kajian 
menunjukkan bahawa nisbah pengambilan andrographolide adalah 1.208 dan 
menunjukkan bahawa andrographolide tidak mungkin sebagai substrat kepada hOAT1. 
Andrographolide juga tidak mungkin adalah perencat kepada hOAT1 disebabkan nilai 
IC50 andrographolide tidak dapat ditentukan pada kepekatan tertinggi yang diuji. Di 
samping itu, andrographolide tidak menunjukkan sebarang perubahan ketara pada 
xxiii 
 
mRNA dan protein hOAT1 dalam sel CHO-hOAT1. Kesimpulannya, andrographolide 
bukan merupakan substrat, perencat dan pencetus kepada hOAT1. 
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THE EFFECTS OF ANDROGRAPHOLIDE ON THE HUMAN ORGANIC 
ANION TRANSPORTER 1 (hOAT1) AND PREDICTION OF ITS DRUG-
HERB INTERACTION RISKS 
 
ABSTRACT 
 Interest in the use of medicinal herbs and herbal products has grown rapidly 
throughout the world. The popularity of herbal constituents makes it important to 
understand potential interactions between herbs and modern medicine. Drug 
transporters have been recognized to play a major role in drug absorption, distribution, 
metabolism and elimination and hence, clinically significant transporter-mediated 
drug interactions can occur. Human organic anion transporter 1 (hOAT1) plays a key 
role in the distribution and elimination of a variety of endogenous substance and 
xenobiotics. Andrographis paniculata Nees has been widely used for treating 
common colds, diarrhea, inflammation and upper respiratory tract infections. In this 
study, andrographolide, a major bioactive compound isolated from A. paniculata Nees, 
was evaluated for its effects on hOAT1-mediated uptake. Recombinant CHO-K1 cell 
line stably expressing hOAT1 (CHO-hOAT1 cells) was established to carry out 
hOAT1-mediated uptake transport activity. The expression of hOAT1 in CHO-hOAT1 
cells was confirmed by RT-qPCR and Western blot analysis. The uptake transport 
assay was used to determine if andrographolide is a substrate or inhibitor of hOAT1. 
The results showed that the uptake ratio of andrographolide was 1.208, indicating that 
andrographolide is unlikely to be a substrate of hOAT1. Andrographolide is also 
unlikely an inhibitor of hOAT1 as the IC50 value of andrographolide was not 
determined at the highest concentration tested. In addition, andrographolide did not 
exhibit any significant changes on mRNA and protein expression of hOAT1 in the 
xxv 
 
CHO-hOAT1 cells. In conclusion, andrographolide is unlikely to be a substrate, 
inhibitor or inducer for hOAT1.  
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CHAPTER 1 
INTRODUCTION 
1.1 Drug interaction 
A drug interaction is a situation in which the disposition of one drug is altered 
by another when both are administered together (Mick, 2005). Drug interactions can 
range in severity from theoretical to clinically significant, sometimes prolonging 
morbidity and even death. However, benefit may be obtained from drug interactions 
that increase drug exposure, improve therapeutic outcome and minimize side effects 
(Piscitelli and Rodvold, 2005). Drug interactions occur not only with other drugs, but 
also with herbal supplements and food, leading to drug-herb interactions and drug-
food interactions respectively.  
 
1.1.1 Drug- drug interaction 
As large number of drugs are introduced every year, drug-drug interactions 
become an important aspect of drug development, especially for safety (Manzi and 
Shannon, 2005). Drug-drug interactions (DDI) can cause profound clinical effects, 
either by reducing therapeutic efficacy or enhancing toxicity of drugs. Drug-drug 
interaction is one of the main cause for drug withdrawal from the market (Huang et al., 
2008). Mibefradil, a drug used to treat high blood pressure or chest pain, has been 
withdrawn from U.S market due to its interaction with others drugs. It has been 
implicated in various case reports as interacting with cyclosporine, statins and 
cisapride; in some cases, renal failure and torsades de pointes were reported (Qureshi 
et al., 2011). Similarly, cases of torsades de pointes have been reported when 
cisapride was administered with other drugs that inhibited cytochrome P450 3A4 
2 
 
isoenzyme (CYP3A4) (Yaffe and Aranda, 2010). Cisapride was removed from the 
U.S. market in 2000 (Wynn et al., 2009).  
With the seemingly constant flow of new therapeutic drugs and new treatment 
indications for existing medications, polypharmacy is increasingly common, 
especially among elderly patients (Lin, 2003). Polypharmacy is defined as concurrent  
use  of multiple  drugs in one prescription. As the number of medications taken by a 
given patient increases, so does the risk of drug interactions. The risk of drug 
interactions is speculated to increase from approximately 6% in patients taking only 
two medications to 50% in those taking five medications and 100% in those taking ten 
medications (Johnson et al., 1994). Concomitant use of antibiotics among warfarin 
users are associated with a high risk of overanticoagulation (Juurlink, 2007). In this 
case, antibiotic medications (quinolones, sulfonamides and azole antifungals) interact 
with warfarin and increase the risk of major bleeding through disruption of intestinal 
flora that synthesize vitamin K, and inhibition of CYP isoenzymes which metabolize 
warfarin (Juurlink, 2007; Schelleman et al., 2008).   
While recognition of adverse drug-drug interactions is important, the 
recognition and appropriate use of beneficial drug-drug interactions is equally 
important task in clinical practice (Yadav, 2008). The use of ritonavir to enhance 
blood concentrations of other protease inhibitors in antiretroviral treatment of human 
immunodeficiency virus (HIV) is an example of a beneficial drug-drug interaction 
that provides enhanced viral suppression (Zeldin and Petruschke, 2004).  
Therefore, the potential for interactions with medications should always be 
considered when administering or prescribing any drug. With new drugs entering the 
market at a rapid pace, identification of new clinically significant drug interactions is 
essential.  
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1.1.2 Drug-food interaction 
A food-drug interaction occurs when a food, or one of its active ingredients, 
interferes with the way a drug acts in the human body (Bobroff et al., 2009). Diet and 
lifestyle can sometimes have a significant effect on how drugs behave in the human 
body. These interactions may occur out of accidental misuses or due to lack of 
knowledge about the active constituents found in the food.  The main cause of 
clinically relevant food-drug interactions is food-induced changes in the 
bioavailability of the drug (Bushra et al., 2011).  
Food-drug interaction is a common hidden problem encountered in clinical 
practice. Food intake can influence the effectiveness of an antibiotic, one of the drugs 
that are widely prescribed in medical practice. Co-administration of ciprofloxacin 
with milk products which are rich sources of divalent ions, such as calcium and 
magnesium decrease the absorption of ciprofloxacin (Papai et al., 2010). In addition, 
eating some vegetables that high in Vitamin K such as broccoli, asparagus, kale and 
parsley can interfere with the effectiveness and safety of warfarin therapy (Bushra et 
al., 2011).  
Several fruits and berries such as grapefruit, sevillian orange, pomelo and star 
fruit contain furanocoumarins that inhibit CYP3A4 enzymes, which plays important 
role in drug metabolism (Molden and Spigset, 2007). A number of studies have 
documented that furanocoumarins present in grape fruit juice increase the oral 
bioavailability of medications which are CYP3A4 substrates like felodipine, 
midazolam, and cyclosporine and resulted in their concentrations to increase to toxic 
levels (deCastro et al., 2007). The in vitro data also suggest that compounds present in 
grapefruit juice are also inhibitors of drug transporters such as P-glycoprotein (P-gp) 
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and organic-anion transporting polypeptide (OATP) (Dresser et al., 2002; deCastro et 
al., 2007).  
Food-drug interactions may influence the safety and efficacy of drug therapy, 
as well in the nutritional status of the patient. Therefore, it is recommended that 
patients should ask for advice from doctors and pharmacists about their food intake so 
that such interactions can be avoided.  
 
1.1.3 Drug-herb interaction 
Interest in the use of medicinal herbs and herbal products has grown rapidly 
throughout the world (Kim et al., 2013). According to the World Health Organization 
(WHO), about 70% to 80% of the world population relies mainly on herbal medicine 
for their primary health care (WHO, 2000). Herbal medicine usage is not only popular 
among individuals, but also among primary health care provider in some developing 
countries.  
The popularity of herbal medicine makes it important to understand potential 
interactions between such properties and prescribed drugs. Drug-herb interactions 
refer to the possibility that some herbal constituents may alter the pharmacologic 
effects of conventional drug given concurrently, or vice versa. The results may be 
either enhanced or reduced drug or herb effects, or the appearance of a new effect that 
is not anticipated from use of the drug or herb alone (Wynn and Fougere, 2007). The 
likelihood of drug-herb interactions could be higher than drug-drug interactions, 
simply because drugs usually contain single chemical entities, while herbal 
preparations contain a mixture of pharmacologically active constituents (Fugh-
Berman and Ernst, 2001).  
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Drug-herb interaction is one of the most important clinical consequences and 
has been reported in various case reports (Fasinu et al., 2012). Several herbal 
medicines have been reported for their adverse drug reactions and interactions with 
prescription medications. Ginkgo biloba, one of the popular traditional Chinese 
medicines has been reported for its possible interaction with aspirin, ibuprofen and 
warfarin resulting in spontaneous bleeding (Chavez et al., 2006). Based on 
preliminary studies, ginseng, a staple Chinese medicine, may increase the risk for 
hypoglycemia. Therefore, concurrent use of ginseng with anti-diabetic medication 
may increase the risk for hypoglycemia (Chavez et al., 2006). Ginseng product which 
contained germanium may have resulted in the interaction with furosemide as 
concomitant use of ginseng and furosemide has been shown to decrease the diuretic 
effects of furosemide (Becker et al., 1996). St. John’s wort, also known as Hypericum 
perforatum, is one of the most extensively studied herbal products. Concurrent use of 
St. John’s wort with serotonin selective re-uptake inhibitors and other antidepressants 
may increase the risk for serotonin syndrome and other central nervous system 
reactions (Chavez et al., 2006). Case reports of likely or possible serotonin syndrome 
associated with use of St. John wort have been reported with buspirone, loperamide, 
nefazodone, paroxetine, sertraline and venlaxafine (Fugh-Berman and Ernst, 2001).  
While drug-herb interactions become more prevalent and reports of adverse 
effects continue to increase, the guidelines for toxicity evaluation and scheduling of 
herbal medicines are lacking. United States Food and Drug Administration (FDA) 
mandate that only medicines have to be proven to be safe before being released to the 
market (Zamri, 2014). Herbal products which are classified as dietary supplements are 
not regulated as medicines by the FDA as long it is not marketed under the indication 
of preventing diseases. In many cases herbal products can be marketed without 
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providing evidence of safety or efficacy. As such, more clinically relevant research is 
required in this area as current information on drug-herb interaction is insufficient for 
clinical application (Fasinu et al., 2012).   
 
1.2 Pharmacokinetic and pharmacodynamic of drug-herb interaction 
In terms of mechanisms, drug interactions can be broadly categorized as either 
pharmacodynamic or pharmacokinetic-based interaction. Pharmacodynamic 
interactions refers to interactions in which drugs influence each other’s effects 
directly (Cascorbi, 2012). Pharmacodynamic interactions may occur when a drug has 
either additive or antagonist effect in relation to another drug. The underlying 
mechanisms include competition at molecular or cellular sites of action. An additive 
effect occurs when selective serotonin reuptake inhibitors (SSRIs) such as citalopram 
are taken simultanueously with nonsteroidal anti-inflammatory drugs (NSAIDs) 
(Andrade et al., 2010). SSRIs inhibit the transport of serotonin into the platelets, 
leading to further impairment of function and enhancing the risk of upper 
gastrointestinal bleeding. The risk of SSRI-associated upper gastrointestinal bleeding 
is further increased with the concurrent use of NSAIDs including aspirin and 
ibuprofen. Conversely, antagonist effect occurs when drugs with opposing effects 
reduce the response to one or both drugs. NSAIDs (ibuprofen and piroxicam) which 
tend to increase blood pressure may inhibit the antihypertensive effect of drugs such 
as ACE inhibitors if both drugs prescribed together at the same time (Pavlicevic et al., 
2008).  
Pharmacokinetic interactions result from an alteration of the absorption, 
distribution, metabolism and elimination processes of a drug substance by another 
compound when they are given concomitantly (Zhang et al., 2009). The risks of 
7 
 
pharmacokinetic drug interaction includes two major adverse drug effects namely, 
pharmacotoxicity and treatment failure. Pharmacokinetic interactions have been the 
main focus for both the FDA and European Medicines Agency (EMA) guidelines 
(Prueksaritanont et al., 2013).  
 Absorption is the entry of drug substances into the systemic circulation via 
various ways such as the mucous membranes of the gut or lungs, the skin, or from the 
site of an injection (Baynes and Hodgson, 2004). Absorption of two drugs at or 
around the same time may result in clinically significant drug interactions. Antibiotics 
such as the fluoroquinolones and tetracyclines will bind to iron, calcium and 
magnesium in antacids if given simultaneously (Yadav and Yadav, 2008). The 
concurrent use of these compounds result in treatment failure and the emergence of 
resistant organisms as the antibiotics will be excreted with little or no systemic 
absorption of the antibiotics (Manzi and Shannon, 2005). 
 Following absorption into the systemic circulation, the drug is distributed 
throughout the body. Distribution of drugs depend on total body water, extracellular 
fluid, percentage of adipose tissue and plasma protein binding (Manzi and Shannon, 
2005). Drug interactions affecting distribution include competition for the binding 
sites on plasma protein (Patsalos and Perucca, 2003). According to a case report 
published by Carvalho and co-workers, a 12 years old patient with refractory epilepsy 
syndrome was presented with phenytoin toxicity, following a concomitant treatment 
with both phenytoin and valproic acid (Carvalho et al., 2014). Concurrent use of 
phenytoin with valproic acid increases the free fraction of phenytoin due to 
competition for the same binding sites. The high level of free fraction of phenytoin 
eventually increases the toxicity of phenytoin (Troy, 2006). 
8 
 
Metabolism is the enzymatic conversion of a drug into more water soluble 
metabolites that are suitable for excretion through the kidneys. Most of the drug 
metabolism processes occur in the liver (Troy, 2006). Drug metabolism is divided into 
2 phases, namely, phase I and phase II reactions. Phase I reactions include the 
processes of oxidation, hydrolysis and reduction, resulting in a compound that is 
generally less toxic and more hydrophilic (Manzi and Shannon, 2005). On the other 
hand, phase II reactions include glucuronidation, sulfation, acetylation and 
methylation, primarily result in the termination of biologic activity of the drug 
(Gibson and Skett, 2001). In fact, most of drug interactions occurring during 
metabolism are the result of inhibition or induction of CYP enzymes (Palleria et al., 
2013). The CYP enzymes are unique isoenzymes found primarily in the liver and are 
responsible for the metabolism process of many drugs and toxins. Concurrent drug 
therapy can inhibit drug-metabolizing enzymes and result in toxicity. Erythromycin is 
a macrolide antibiotic and has been reported cause drug interactions when prescribed 
with statin (atorvastatin and simvastatin) (Becker, 2011). Erythromycin inhibits the 
activity of CYP3A4 and thus, raises the plasma level of statins which are metabolized 
by CYP3A4. This potential drug interaction eventually increases the toxicity of statins. 
In a case report, a 70 years old man developed myalgia and fatal rhadomyolysis after 
receiving concomitant treatment of erythromycin and simvastatin (Dubash et al., 
2010).   
 Elimination is the excretion of drug molecules from the body, usually by 
removal of the parent drug or metabolites through the kidney (Lee et al., 2006). Renal 
elimination can be affected by any drugs that affect glomerular filtration rate, tubular 
secretion and tubular reabsorption (Bonate and Howard, 2005). Drug interactions can 
inhibit renal tubular secretion and assist in maintaining a higher serum concentration 
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than the body would normally allow (Yaffe and Aranda, 2010). A notable example of 
this drug interaction, used long ago intentionally for therapeutic benefit, is the 
combination of probenecid and penicillin to increase antibiotic serum concentrations 
(Piscitelli and Rodvold, 2005). In the kidney, probenecid reduces the active tubular 
secretion of penicillin by inhibiting organic anion transporters (OATs) in the 
basolateral membrane of the proximal tubular cells. Thus, the clearance of penicillin 
will be reduced leading to an increase in plasma concentration and extending half-lilfe 
of penicillin (Cunningham et al., 1981). This effect is exploited therapeutically in the 
treatment of infections.  
 Effects of one drug on the absorption, distribution, metabolism or excretion of 
another drug may lead to change in exposure leading to altered response and caused 
numerous drug interactions have been identified. Thus, pharmacokinetic drug 
interaction is recognized as an important consideration in drug development and 
regulatory review.   
 
1.3 Drug transporters 
Evaluation of a new chemical entity’s drug-drug interaction potential is an 
integral part of drug development and regulatory review prior to its market approval 
(Zhang et al., 2006). To date, CYP-mediated drug interactions have been suggested as 
a critical first step in the assessment of drug interactions and are now widely accepted 
by the pharmaceutical industry (FDA, 2012).  In addition to the effects of drug 
metabolizing enzymes on the pharmacokinetic drug interactions, there is an increasing 
recognition that transporters play an important role in modulating drug absorption, 
distribution, metabolism and elimination (Zhang et al., 2009). Clinical 
pharmacokinetic drug-drug interaction studies have suggested that transporters often 
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work together with drug metabolizing enzymes in drug absorption and elimination 
(Giacomini et al., 2010).  
Functionally, transporters can be classified into two major superfamilies 
namely, the ATP-binding cassette (ABC) family transporters and solute carrier (SLC) 
family transporters. ABC transporters include P-glycoprotein (P-gp), multidrug 
resistance protein (MRP) and breast cancer resistance protein (BCRP) are efflux 
transporters which bind to ATP and use the energy to drive the transport of various 
drugs across the plasma membrane (Konig et al., 2013). SLC transporters such as 
organic anion transporting polypeptides (OATPs), organic anion transporters (OATs) 
and organic cation transporters (OCTs) are responsible to mediate the flow of various 
drugs over the cell membrane ranging from the cellular uptake to the absorption of 
drugs (Roth et al., 2012). Both ABC and SLC transporters determine plasma and 
concentration of a broad variety of drugs. Transporters are expressed in the small 
intestine, liver and kidney, particularly important in drug disposition and drug-drug 
interactions (Muller and Fromm, 2011). Transporters expressed in blood-tissue barrier 
have been shown to protect sensitive tissues from potentially toxic compounds (Konig 
et al., 2013). 
 The major underlying mechanism of transporter-based drug interactions may 
be inhibitory, inductive or both. Such transporter-based interactions will be clinically 
significant if elimination of the affected drug or the distribution into a target tissue is 
mediated primarily by the transporter and that the interaction results in the 
concentration of the affected drug at the site of action or toxicity to fall outside of the 
therapeutic range (Endres et al., 2006). Furthermore, transporter-based interactions 
may affect the concentration of the substrate in a particular tissue without altering the 
blood or plasma concentration of the substrate. Interactions occurring at the blood-
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brain barrier do not affect the drug exposure in the circulating blood but only the 
pharmacological and/or toxicological effect of the drug (Marzolini et al., 2011) . 
Cyclosporine A, an inhibitor of P-gp affected the distribution of verapamil, a P-gp 
substrate into the brain by inhibiting P-gp efflux, without significantly affecting the 
plasma or blood concentration of the verapamil (Sasongko et al., 2005). This is 
possible because the amount of drug distributing into the brain is only a small fraction 
of the total amount of the drug in the body. Sometimes, transporter-based drug 
interactions lead to beneficial effect instead of clinical consequences. Co-
administration of probenecid with cidofovir reduced the nephrotoxicity of cidofovir 
due to inhibition of human organic anion transport (hOAT) of cidofovir into the 
kidney epithelial cells by probenecid (Endres et al., 2006). 
As transporter-mediated drug interactions are being increasingly identified, it 
is important to predict transporter-based drug interactions for evaluation in the drug 
discovery and development process. Thus, FDA and EMA guideline on the 
investigation of drug interactions provides recommendations on the seven most 
relevant drug transporters, namely P-gp, BCRP, organic anion transporting 
polypeptide 1B1 (OATP1B1), OATP1B3, organic anion transporter 1 (OAT1), OAT3 
and organic cation transporter 2 (OCT2) (FDA, 2012).  
 
1.4 Organic anion transporter (OAT) 
Among the transporters, organic anion transporters (OATs), which belong to 
the amphiphilic solute carrier transporters family 22A (SLC22A), are key 
determinants in the absorption, distribution and elimination of a diverse array of 
exogenous and endogenous compounds (Sweet, 2005). OATs are characterized by 
broad substrate specificity and the ability to interact with a wide variety of 
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compounds that are not only small, amphiphilic organic anions but also uncharged 
molecules and even some organic cations (Riedmaier et al., 2012). OATs interact 
with many clinically relevant and commonly prescribed anionic drugs including β–
lactam antibiotics, diuretics, anti-cancer drugs, NSAIDs, and anti-HIV therapeutics 
(Sekine et al., 2000). As a consequence of the multi-specific substrate recognition of 
the transporter, clinically significant transporter-mediated drug interactions can occur. 
Drugs in the plasma may compete for the transporter processes, thus mutually 
influencing each other’s pharmacological and toxicological profile (Duan et al., 2012). 
Cloned OATs have several common structural features including 12 
transmembrane domains flanked by intracellular amino- and carboxyl termini.  A 
cluster of potential glycosylation sites localized in the first extracellular loop between 
transmembrane domains 1 and 2, and multiple phosphorylation sites present in the 
intracellular loop between transmembrane domains 6 and 7 and in the carboxyl 
terminus. Figure 1.1 shows the predicted transmembrane topology model of OAT 
family.  
To date, several members of the OAT family have been identified, which 
differ from each other by their localization, expression level and substrate specificity. 
In human kidney, human organic anion transporter 1 (hOAT1/SLC22A6), hOAT2 
(SLC22A7) and hOAT3 (SLC22A8) are localized in the basolateral membrane, and 
hOAT4 (SLC22A11), hOAT10 (SLC22A13) and human urate transpoter 1 
(hURAT1/SLC22A12) are found in the apical cell membrane of proximal tubule cells, 
respectively. Among OATs, mRNA levels of hOAT1 and hOAT3 were much higher 
than those of other organic ion transporters in the human kidney cortex (Motohashi et 
al., 2002). In addition, many previous studies have reported that hOAT1 and hOAT3  
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Figure 1.1  Predicted transmembrane topology model of OAT family. Twelve  
transmembrane domains are numbered from 1-12. Potential 
glycosylation sites are denoted by tree-like structures and 
phosphorylation sites are labeled as “P”. [Adapted from: Duan and 
You, 2010] 
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actively mediated tubular uptake of various therapeutics (Robertson and Rankin, 
2006). Modulators of hOAT1 and hOAT3 activities are known to have high potential 
for drug interactions in the combination therapy and alter the pharmacokinetics of 
various drugs particularly that are eliminated from the body mainly via urinary 
excretion (Konig et al., 2013). 
In the kidney, hOAT1 and hOAT3 mediate a tertiary transport mechanism to 
move organic anions across the basolateral membrane into the proximal tubule cells 
for subsequent exit across the apical membrane into the urine for excretion (Duan and 
You, 2010). Through this tertiary transport mechanism, Na
+
/K
+
-ATPase maintains an 
inwardly directed Na
+
 gradient from blood to cell. The Na
+
 gradient then drives a 
sodium dicarboxylate cotranspoter, sustaining an outwardly directed dicarboxylate 
gradient that is utilized by hOAT1, hOAT3 or both, to move the organic anion 
substrates into the cell. This process indirectly links organic anion transport to 
metabolic energy and the Na
+
 gradient, allowing the entry of a negatively charged 
substrate against both its chemical concentration gradient and the electrical potential 
of cell (Duan and You, 2010). Figure 1.2 shows model for basolateral OAT pathway. 
hOAT1 interacts with more than a hundred compounds, and its substrates 
include endogenous compounds, such as dicarboxylates, cyclic nucleotides, 
prostaglandins, and urate as well as exogenous ones, such as drugs and environmental 
compounds (Sekine et al., 2000). hOAT3 exhibits a wide substrate selectivity similar 
to hOAT1. OAT3 mediates the high-affinity transport of estrone sulfate, 
dicarboxylates and various drugs, even including the cationic drug cimetidine (Sekine 
et al., 2006). The substrate specificities of hOAT1 and hOAT3 overlap, but hOAT1 
has a larger contribution to low-molecular weight of hydrophilic organic anion as 
compared to hOAT3 that accepts more bulky amphiphatic anions (Tahara et al., 2006).  
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Figure 1.2 Model for basolateral OAT pathway. SDCT2: Na
+
- coupled 
dicarboxylate cotransporter-2. OAT1/3: organic anion transporter 1 
and 3. OA
-
: organic anion (endogenous and exogenous anions). α-KG: 
α-ketoglutarate [Adapted from: Duan and You, 2010]. 
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1.5 Organic anion transporter 1(OAT1/SLC22A6) 
1.5.1 Biochemistry of hOAT1 
OAT1 was the first organic anion transporter to be cloned and functionally 
characterized from human, monkey, pig, rabbit, rat and mouse (Buckhardt, 2012). 
Within the HUGO nomenclature, the gene for OAT1/Oat1 has been assigned the 
name SLC22A6 for humans and Slc22a6 for the other species. The mammalian OAT1 
is composed of approximately 550 amino acids (aa) residues.  In humans, four splice 
variants of hOAT1 (563, 550, 506 and 519 aa) occur in the kidney. The longer splice 
variants are hOAT1-1 and hOAT-2. hOAT1-1 is composed of 563 amino acids while 
hOAT1-2 is composed of 550 amino acids. The two shorter, non-functional splice 
variants are known as hOAT1-3 and hOAT1-4, respectively. The longer splice 
variants have identical transport functions while the shorter two have lack of transport 
capability (Bahn et al., 2004).  
The gene for human OAT1 is located on chromosome 11q12.3, near to the 
human OAT3 gene. Secondary structure of OAT1 consists of twelve putative 
transmembrane helices with nitrogen and carbon termini located at the cytosolic side 
of the plasma membrane, a large extracellular loop between transmembrane helices 1 
and 2, and a large intracellular loop between helices 6 and 7 (Roth et al., 2012). 
Moreover, the large extracellular loop between transmembrane helices 1 and 2 carries 
several glycosylation sites and the carbon terminus, whereas the intracellular loop 
between transmembrane helices 6 and 7 carry several consensus sequences for 
phosphorylation by protein kinases (Roth et al., 2012).  
Human OAT1 messenger RNA (mRNA) is strongly expressed in the kidneys 
(Bleasby et al., 2006). Considerably low mRNA levels of hOAT1 are also found in 
brain, lung, skeletal muscles and stomach (Fromm and Kim, 2011). 
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Immunocytochemistry revealed that hOAT1 proteins are located at basolateral 
membrane of renal proximal tubule cells.. This location is consistent with the 
important role of hOAT1 in uptake of drugs from the blood into proximal tubule cells 
and may thus be regarded as a transporter specific to kidneys.  
 
1.5.2 Structure and active site of hOAT1 
As hOAT1 plays a significant role in handling of endogenous and exogenous 
organic anion by excretory and barrier tissues, the molecular level structure model of 
hOAT1 is the particular interest. Unfortunately, like other membrane proteins, there is 
a lack of structural information on OATs. Therefore, to overcome problems with 
protein crystallization, development of computational models to predict structure 
based on two-dimensional fold recognition between the target (a protein of unknown 
structure) and the template (a protein of known structure) is one of the emerging 
methods to create the homology model of the membrane protein (Perry et al., 2006).  
OATs share many structural features with major facilitator superfamily (MFS) 
proteins despite weak sequence similarities. MFS protein is one of the largest groups 
of secondary active transporters conserved from bacteria to humans (Yan, 2013). In 
particular, OATs possess MFS hallmark including 12 transmembrane α-helices with 
cytosolic nitrogen and carbon termini, a long intracellular loop that connects the two 
6-helix halves, a sequence length between 400 and 600 amino acids, and a RXXXR 
signature sequence conserved between loop 2-3 (Maiden et al., 1987; Pao et al., 1998; 
Hirai et al., 2004). Among the MFS proteins, X-ray crystal structure of glycerol 3- 
phosphate (GlpT, SLC37A2) and the lactose permease (LacY) of Escherichia coli are 
available and provide templates for OATs structure (Pelis et al., 2011). GlpT (Protein 
Data Bank code 1pw4) was selected as a template for the hOAT1 model because 
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GlpT transports substrate as an antiporter was similar to the hOATs despite their low 
sequence identity (14%) (Perry et al., 2006). A three-dimensional model of hOAT1 
based on the structure of GlpT has been generated and illustrated in Figure 1.3. 
According the study done by Perry and co-workers, the putative active site for 
hOAT1 was predicted and located in the cavity formed by the 12 transmembrane 
domains. The structural model of hOAT1 shows that helices 5, 7, 8, 10 and 11 
surround an electronegative putative active site with a volume of ~830Å
3
 (Perry et al., 
2006). This active site opens to the cytoplasm and is surrounded by residues Tyr230 
(domain 5), Lys431 (domain 10) and Phe438 (domain 10). In addition, the residues 
Tyr230 and Phe438 have been identified as important amino acid residues in OAT1 
substrate recognition and translocation based on the model and experimental 
mutations carried out (Perry et al., 2006). Residue Arg466 is also one of the residues 
surround the putative active cavity of hOAT1 in the helix 11 and is a major 
determinant in substrate translocation (Rizwan et al., 2007). Taken together, it 
appears that basic amino acid residues in trans-membrane helices 8, 10, and 11 play a 
role in dicarboxylate binding and these residues are Lys382 (domain 8), Lys431 
(domain 10) and Arg466 (domain 11) (Kaufhold et al., 2011). 
 
 
 
 
 
 
 
 
19 
 
 
Figure 1.3 A three-dimensional model of hOAT1 based on the structure of GlpT. 
[Adapted from: Pelis et al., 2011] 
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1.5.3 Substrates of hOAT1 
Under physiologic conditions, OAT1 are responsible as an antiporter 
exchanging intracellular α-ketoglutarate against extracellular organic anions and 
drugs. OAT1 is well-known for its very broad substrate specificity. The prototypical 
substrate to test heterologously expressed OAT1 in vitro is radiolabeled p-
aminohippurate (PAH). Inhibition of PAH transport indicates an interaction of the 
tested compound with the investigated transporter, but does not necessarily implicate 
its transport (Burckhardt, 2012). Using various expression systems, the Km value for 
PAH uptake by human OAT1 is ranged between 3.1 µM and 113 µM with a mean of 
28.5 µM (Burckhardt, 2012).  Furthermore, due to its broad substrate specificity, 
hOAT1 also is a key mediator in the distribution and renal tubular secretion of a 
multitude of endogenous substances, drugs and numerous active compounds from 
herbal medicines and food such as phenolic acids and flavonoids (Hong et al., 2007; 
Wang and Sweet, 2012a). The substrates of hOAT1 is listed in Table 1.1.  
 
1.5.4 Inhibitors of hOAT1 
Inhibition of human OAT1 at the basolateral membrane of renal proximal 
tubule cells reduces the active tubular secretion of drugs. As a consequence, drug 
clearance is reduced and plasma drug concentrations of substrate drugs are elevated. 
Probenecid is the prototypical inhibitor of the OAT1 and OAT3 (Muller and Fromm, 
2011). This drug was introduced in the 1950’s to decrease the renal excretion and 
prolong the plasma half-life of penicillins (Cunningham et al., 1981). The major route 
of the excretion of penicillin, renal tubular secretion is efficiently inhibited by 
probenecid. Meanwhile, it is also known that probenecid lowers serum uric acid 
concentrations and it has been used as uricosuric agent for the prevention of gout  
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Table 1.1 Compounds interacting with hOAT1 
Compounds Substrates Inhibitors References 
Endogenous 
substances 
 cGMP 
 Dicarboxylate α-
ketoglutarate 
 Prostaglandin 
 Purine metabolite 
 Urine 
 Dicarboxylate α-
ketoglutarate 
 Urate  
(Sekine et al., 1997; Lu et al., 1999; Kimura et al., 
2002; Sugawara et al., 2005; Cropp et al., 2008; 
Hagos et al., 2008; Sato et al., 2008) 
ACE inhibitors  Captopril 
 Quinapril 
- (Ueo et al., 2007; Yuan et al., 2009) 
Angiotensin II 
receptor blockers 
 Olmesartan  Candesartan 
 Losartan 
 Pratosartan 
 Telmisartan 
 Valsartan 
(Yamada et al., 2007; Sato et al., 2008) 
Diuretics  Bumetanide 
 Furosemide 
 Loop diuretics 
 Bumetanide 
 Furosemide 
 Torasemide 
(Hasannejad et al., 2003; Bahn et al., 2004; Hagos 
et al., 2007) 
Statins  Fluvastatin 
 Simvastatin 
 
 
- (Takeda et al., 2004; Windass et al., 2007) 
ẞ- lactam 
antibiotics 
 Tetracyclines  Tetracyclines 
 Cefazolin 
 Cefoperazone 
 Cefadroxil 
(Babu et al., 2002; Ueo et al., 2005) 
